# MetaNovas AI

> MetaNovas (MetaNovas Biotech) is an AI-driven biotech company building a drug and disease discovery platform that compresses the slow, failure-prone front end of R&D. Its stack of proprietary engines - MetaNLP, MetaKG, MetaOmics and MetaPep - reads millions of scientific documents, maps biomedical knowledge, and designs bioactive peptides before anything reaches a lab bench. The company applies that science to longevity beauty, cosmeceuticals, medical aesthetics and functional foods, working with global brands while pursuing novel targets, drug repurposing and precision-formulated consumer health products.

- **Founded:** 2021
- **Headquarters:** Foster City, California, United States
- **Founders:** Meijie Wang (Co-Founder & CEO), Lun Yu (Co-Founder & CTO)
- **Team size:** ~12 employees (11-50 range reported)
- **Products:** MetaNLP, MetaKG, MetaOmics, MetaPep, Peptide product pipeline
- **Notable:** Recognized at the 2023 IFSCC Congress for AI-led cosmetic science, Named among the 250 Most Promising Early-stage Digital Health Ventures, Best AI-Led Functional Food Development Firm of 2023 (LUXlife Magazine)

## Products & services

- **MetaNLP** — A natural language engine that processes millions of scientific documents into structured, accessible data for navigating complex biological domains.
- **MetaKG** — A biomedical knowledge graph that connects biology, chemistry and disease relationships to surface novel discoveries and product development paths.
- **MetaOmics** — A multi-omics analysis platform that designs precision-targeted products for specific demographics based on omics data.
- **MetaPep** — A peptide design engine combining deep learning and molecular simulation to generate and screen bioactive peptides before synthesis.
- **Peptide product pipeline** — AI-designed bioactive peptides (e.g. MetaAMP and MetaPep-Ocean series) for longevity beauty, cosmeceuticals and functional applications.
- **AI drug & disease discovery platform** — End-to-end ML platform to identify novel disease targets, screen potential drugs, repurpose existing drugs for new indications and predict ADMET properties.

## Achievements

- Recognized at the 2023 IFSCC Congress for AI-led cosmetic science
- Named among the 250 Most Promising Early-stage Digital Health Ventures
- Best AI-Led Functional Food Development Firm of 2023 (LUXlife Magazine)
- Reports 45% higher R&D success rate via its AI-enabled approach
- Selected for the 2023 MIT Startup Showcase in Seoul
- Closed a Series A led by Hillhouse Ventures in December 2024

## Latest updates

- **2026-04** — Co-founder & CTO Dr. Lun Yu presents 'Reprogramming Youth: How AI-Engineered Peptides Unlock Longevity Beauty' at in-cosmetics Global 2026 in Paris.
- **2026-03** — Most recent funding activity reported (Series A stage, ~$10M total funding referenced).
- **2024-12** — Closed Series A round led by Hillhouse Ventures with participation from Baoding Ventures.

## Links

- Website: https://metanovas.com
- LinkedIn: https://www.linkedin.com/company/metanovas-biotech

---

Profile page: https://yespress.io/metanovas-ai
Published by YesPress — https://yespress.io
Last updated: 2026-06-13